Policy Intelligence
Billing gaps, coding inequities, and funding analysis
| Condition | ICD-10 Codes | Status | Impact Level |
|---|---|---|---|
| Lyme Disease | A69.20A69.21A69.22A69.23A69.29 | Has code | high |
| Long COVID | U09.9 | Has code | moderate |
| ME/CFS | G93.3 | Has code | high |
| Alpha-gal Syndrome | None | No code | critical |
| POTS | G90.3 | Has code | high |
| Fibromyalgia | M79.7 | Has code | moderate |
- No dedicated code for Post-Treatment Lyme Disease Syndrome (PTLDS)
- No code distinguishes chronic Lyme from acute reinfection
- No code for tick co-infections (Babesia, Anaplasma often coded separately)
Impact: PTLDS patients are coded under generic symptom codes, making surveillance of post-treatment complications impossible. Research funding allocation cannot target a population that is invisible in billing data.
- G93.3 is shared with 'postviral fatigue syndrome' broadly
- Many providers use fatigue NOS codes instead
- No severity grading (mild, moderate, severe, very severe)
Impact: Provider reluctance to use G93.3 results in massive undercounting. The NIH's $15M/year funding reflects this invisibility: you cannot fund what you cannot measure.
- NO dedicated ICD-10 code exists
- Patients coded under generic allergy codes (T78.1, L50.0)
- NOT a nationally notifiable disease
- 75% diagnostic undercount as a result
Impact: Without any ICD-10 code, AGS is completely invisible in health surveillance, billing data, and research databases. The 75% diagnostic undercount is a direct consequence. Epidemiological tracking is impossible.
- G90.3 is 'Other disorders of autonomic nervous system' (not POTS-specific)
- Often miscoded as anxiety or panic disorder
- No post-COVID POTS subtype code
Impact: POTS is frequently misdiagnosed as anxiety (average 4+ year diagnostic delay). Without a specific code, the post-COVID POTS surge cannot be tracked through claims data.